Back to search results

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Endometrial Cancer · Recurrent Endometrial Carcinoma · Endometrial Carcinoma · Gynecologycal Cancer · Endometrial Neoplasms

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • National Cancer Center, Kyeonggi-do, South Korea

    Contact: Study coordinator (Myoung Cheol Lim) · mclim@ncc.re.kr · +82-31-920-0856
    Contact: Principal Investigator (Myoung Cheol Lim, Ph.D)

  • Severance hospital, Seoul, South Korea

    Contact: Study coordinator (Jung-Yun Lee) · JUNGYUNLEE@yuhs.ac · +82-2-2228-0571
    Contact: Principal Investigator (Jung-Yun Lee, Ph.D)

  • Korea University Guro Hospital, Seoul, South Korea

    Contact: Study coordinator (Hyun-Woong Cho) · limpcho82@korea.ac.kr · +82-2-2626-1206
    Contact: Principal Investigator (Hyun-Woong Cho, Ph.D)

  • Samsung Medical Center, Seoul, South Korea

    Contact: Study coordinator (Byeong-Gie Kim) · bksong.kim@samsung.com · +82-2-2148-7642
    Contact: Principal Investigator (Byeong-Gie Kim, Ph.D)

  • Seoul Asan Medical Center, Seoul, South Korea

    Contact: Study coordinator (Jeong-Yeol Park) · obgyjypark@amc.seoul.kr · +82-2-3010-3646
    Contact: Principal Investigator (Jeong-Yeol Park, Ph.D)

  • Seoul National University Hospital, Seoul, South Korea

    Contact: Study coordinator (Se Ik Kim) · seikky@naver.com · +82-2-6072-5199
    Contact: Principal Investigator (Se Ik Kim, Ph.D)
View source on ClinicalTrials.gov(opens in a new tab)